key: cord-0018246-hm392tcm
authors: Şahin, Ayça Sultan; Kaya, Ebru; Turgut, Gürsel; Kocataş, Ali
title: Can we use mesenchymal stem cell transplantation for COVID-19 patients in puerperium period?
date: 2021-05-28
journal: J Turk Ger Gynecol Assoc
DOI: 10.4274/jtgga.galenos.2021.2020.0180
sha: 333b168e9d070d1c8b4faddad2fdf9e6a4804160
doc_id: 18246
cord_uid: hm392tcm

nan

To the Editor,

The Coronavirus disease-2019 (COVID-19) pandemic has affected the whole world, and pregnant women and women in the postpartum period have not been spared from its effects. Pregnant women during this pandemic pose an unknown risk to their babies. We followed up pregnant and post-pregnancy COVID-19 patients in this period in the intensive care unit (ICU) and used mesenchymal stem cell (MSCs) transplantation in suitable patients. We aimed to investigate patients with COVID-19 pneumonia and who were hospitalized in the ICU after C-section in the puerperium period and either given or not given MSCs treatment.

A 33 year-old multiparous woman with a history of pregnancy at 33 gestation weeks, admitted with fever (>38 °C) and cough, with a presumptive diagnosis of COVID-19. Chest computed tomography showed patchy ground-glass opacity ( Figure 1 ). On the third day of hospitalization, she had severe dyspnea and tachypnea and delivery was advised, so she underwent C-section with spinal anesthesia. The patient was transferred to ICU after labor with respiratory distress and X-rays showed patchy ground-glass opacities. She was intubated. D-dimer, C-reactive-protein (CRP), and ferritin levels continued to increase up to the tenth day after the C-section. The patient's clinical situation was evaluated as cytokine storm. After tocilizumab treatment, MSC treatment was given twice with two days intervals. At the end of the third week the patient was extubated. X-rays showed dramatic healing of the patchy ground-glass opacity. When she could breath air unassisted, she was discharged from ICU and subsequently to home. 

Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

Mesenchymal stem cells: current clinical progress in ARDS and COVID-19